Our case highlights the enduring effectiveness of lenalidomide in treating serious R/R AITL, including patients with extensive prior treatments, resistance to HDAC inhibitors, and widespread extranodal involvement, notably in the lungs. This evidence concerns the gene HDAC9 and angioimmunoblastic T-cell lymphoma.